- Stocks
- Pharma & Healthcare
- Starsource Mult
Starsource Mult share price
NSE: STARSOURCEPharma & HealthcareBiotechnology
Starsource Mult at a glance
With a market capitalisation of ₹14 Cr, it ranks 3762nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
Its return on equity was −39.4% in FY16. Promoters held 27.89% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹14 CrRank 3762 on NSE
- Price to book
- 0.73×FY16
- EPS (TTM)
- −₹79.11to Q4 FY26
- ROE
- −39.4%FY16
- ROCE
- −38.2%FY16
- Debt to equity
- 0FY16
- Net profit margin
- 0.0%FY16
- Book value / share
- ₹24.49FY16
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Starsource Mult quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | ₹1 Cr | — | — |
| Revenue YoY | — | — | — | — | — | — | — | — |
| Net profit | ₹0 Cr | ₹1 Cr | −₹0 Cr | −₹0 Cr | −₹12 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr |
| Net profit YoY | −34.2% | +38.6% | −125.0% | — | −4,824.0% | −83.6% | — | — |
| Net margin | — | — | — | — | — | 18.9% | — | — |
| EPS | ₹1.64 | ₹4.07 | −₹1.17 | −₹2.26 | −₹78.70 | ₹0.65 | −₹0.58 | −₹0.48 |
Starsource Mult financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Operating profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹1 Cr |
| Net profit | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
| EPS (₹) | ₹2.77 | ₹1.67 | ₹3.73 | ₹0.32 | ₹8.00 | ₹2.28 |
| Cash from operations | ₹5 Cr | ₹2 Cr | −₹0 Cr | −₹1 Cr | ₹1 Cr | −₹0 Cr |
| Total debt | — | — | — | — | — | — |
| Shareholders' equity | — | — | — | — | — | — |
Starsource Mult shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 27.89% | 27.89% | 27.89% | 27.89% | 27.89% | 27.89% |
| Domestic institutions | 0.37% | 0.37% | 0.37% | 0.37% | 0.37% | 0.37% |
| Non-institutions | 71.75% | 71.75% | 71.75% | 71.75% | 71.75% | 71.75% |
Starsource Mult vs peers
The listed Pharma & Healthcare companies nearest to Starsource Mult by market capitalisation.
Ask anything about Starsource Mult
Pivot answers on the live chart with evidence you can check, and tests strategies against STARSOURCE's own history. Try: “Why has STARSOURCE moved over the last three months?” · “Backtest a 50-day moving-average crossover on STARSOURCE over five years” · “Compare STARSOURCE with VENMAX on margins and valuation”
Frequently asked questions about Starsource Mult
What is the market cap of Starsource Mult?
Starsource Mult's market capitalisation is ₹14 Cr (₹14 Cr) at the 22 Oct 2026 close, ranking 3762nd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Starsource Mult?
Return on equity was −39.4% in FY16 and return on capital employed was −38.2% in FY16 (consolidated figures).
Is Starsource Mult a debt-free company?
Starsource Mult is close to debt-free: its debt-to-equity ratio was 0 in FY16.
What is the shareholding pattern of Starsource Mult?
As of 30 Jun 2026: promoters 27.89%, domestic institutions 0.37%, non-institutions 71.75%.
Who are Starsource Mult's competitors?
The listed Pharma & Healthcare companies closest to Starsource Mult by market cap are Venmax Drugs, Zenith Health, Family Care Hos, Colinz Labs, Norris Medicine and Dolphin Medical.
Is Starsource Mult a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Starsource Mult's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on STARSOURCE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text